Evidence map›Paper›PMID 11454656›Full record

ArticleBritish journal of pharmacology2001

Role of cyclic nucleotides in vasodilations of the rat thoracic aorta induced by adenosine analogues.

S M Hourani, K Boon, H M Fooks, D J Prentice

Open access · greenAbstract read
In one paragraph

Article in British journal of pharmacology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Lysophosphatidic acid receptor-2 (LPAMolecular and cellular biochemistry · 2020
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

S M HouraniSchool of Biomedical and Life Sciences, University of Surrey, Guildford, Surrey GU2 7XH.
K Boon
H M Fooks
D J Prentice
University of Surrey · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Although adenosine analogues such as 5'-N-ethylcarboxamidoadenosine (NECA) relax the rat thoracic aorta in a partially endothelium-dependent manner via adenosine A(2A) receptors, others such as N(6)-R-phenylisopropyladenosine (R-PIA) act via an endothelium-independent, antagonist-insensitive mechanism. The role of cyclic nucleotides in these relaxations was investigated in isolated aortic rings using inhibitors of adenylate and guanylate cyclases as well as subtype-selective phosphodiesterase inhibitors. The adenylate cyclase inhibitor 9-(tetrahydro-2-furanyl)-9H-purin-6-amine (SQ 22536; 100 microM) significantly inhibited responses to NECA, but not responses to R-PIA. The type IV (cyclic AMP-selective) phosphodiesterase inhibitor 4-[(3-butoxy-4-methoxyphenyl)methyl]-2-imidazolidinone (RO 20-1724; 30 microM) significantly enhanced responses to NECA and to a lesser extent those to R-PIA. The guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3a]quinoxalin-1-one (ODQ; 100 microM) significantly inhibited responses to NECA and acetylcholine but not responses to R-PIA. The selective phosphodiesterase V (cyclic GMP-selective) inhibitors, zaprinast (10 microM) and 4-[[3',4'-(methylenedioxy)benzyl]amino]-6-methoxyquinazoline (MMQ; 1 microM), had no significant effect on responses to either NECA or R-PIA, but enhanced responses to acetylcholine. These results are consistent with the effects of NECA being via activation of endothelial receptors to release NO which stimulates guanylate cyclase, as well as smooth muscle receptors coupled to stimulation of adenylate cyclase. The lack of effect of zaprinast and MMQ on responses to NECA are likely to be due to simultaneous activation of both adenylate and guanylate cyclases in the smooth muscle, as cyclic AMP reduces the sensitivity of phosphodiesterase V to inhibitors. These results also suggest that the effects of R-PIA are via neither of these mechanisms.

Indexed as

4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinoneAcetylcholineAdenineAdenosineAdenosine-5'-(N-ethylcarboxamide)Adenylyl Cyclase InhibitorsAnimalsAorta, ThoracicDose-Response Relationship, DrugEnzyme InhibitorsIn Vitro TechniquesMaleNitroprussideNucleotides, CyclicOxadiazolesPurinones1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one4-((3,4-(methylenedioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone9-(tetrahydro-2-furyl)-adenineAcetylcholineAdenineAdenosineAdenosine-5'-(N-ethylcarboxamide)Adenylyl Cyclase InhibitorsEnzyme InhibitorsN-(1-methyl-2-phenylethyl)adenosineNitroprussideNucleotides, CyclicOxadiazolesPurinonesQuinazolinesQuinoxalinesVasodilator Agentszaprinast

Identifiers

PMID11454656
PMCPMC1572848
OpenAlexW2100549262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.